OnCo
peoplePerson

Jeremie Calais

Runs the UCLA theranostics trials that test PSMA imaging against conventional scans and lutetium against chemotherapy.

Nuclear medicine physician leading prospective PSMA PET and PSMA radioligand therapy trials, including the head-to-head PSMA PET versus fluciclovine study and dosimetry research.

Role
Associate Professor; Director, Clinical Research Program, Ahmanson Translational Theranostics Division, UCLA
Specialisms
PSMA PETRadioligand therapyClinical trials

Papers

2top
TitleJournalYear
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trialLancet Oncology2019
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohortJournal of Nuclear Medicine2021

Connected

5top

cancers

1
Prostate cancer

technologies

2
PSMA PETRadioligand therapy (beta emitters)

targets

1
PSMA

institutions

1
UCLA Jonsson Comprehensive Cancer Center